Related Experiment Video

Updated: Dec 19, 2025

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

525

[Antidiabetic SGLT-2 inhibitors prevent progression of chronic kidney disease]

Gunnar Henrik Heine1

  • 1AGAPLESION MARKUS KRANKENHAUS, Medizinische Klinik II, Frankfurt am Main, Frankfurt.

Deutsche Medizinische Wochenschrift (1946)
|June 4, 2020
PubMed

Insights

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors show significant kidney-protective effects in patients with chronic kidney disease (CKD). These findings support their use in managing CKD progression, even in non-diabetic individuals.

Area of Science:

  • Nephrology
  • Endocrinology
  • Cardiology

Background:

  • Cardiovascular safety trials of antidiabetic drugs revealed potential kidney benefits of SGLT-2 inhibitors.
  • The CREDENCE study demonstrated SGLT-2 inhibitors slow chronic kidney disease (CKD) progression in diabetic patients with impaired kidney function and albuminuria.

Purpose of the Study:

  • To evaluate the efficacy of SGLT-2 inhibitors in slowing CKD progression across diverse patient groups.
  • To assess SGLT-2 inhibitor effectiveness in non-diabetic CKD patients, those without albuminuria, and patients with advanced CKD.

Main Methods:

  • The DAPA-CKD study investigated the nephroprotective effects of dapagliflozin in CKD patients.
  • The EMPA-KIDNEY study explored SGLT-2 inhibitor benefits in a broad CKD population.

Main Results:

  • The DAPA-CKD trial was stopped early due to overwhelming evidence of dapagliflozin's nephroprotective effects.
  • Emerging data suggests SGLT-2 inhibitors offer significant benefits in slowing CKD progression.

Conclusions:

  • SGLT-2 inhibitors demonstrate substantial nephroprotective effects, extending beyond diabetic patients.
  • New guidelines will likely recommend SGLT-2 inhibitors as a standard CKD treatment, including for those with diabetes and reduced renal function.

More Related Videos

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

843
Assessment of Kidney Function in Mouse Models of Glomerular Disease09:16

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Published on: June 30, 2018

18.4K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
468
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
525
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
490
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
451
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
733
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
203